Purpose: Earlier work has established developmental benchmarks for intelligibility and articulation rate, but the intersection of these two variables, especially within individual children, has received limited attention. This study examines the interaction between intelligibility and speaking rate in typically developing children between the ages 2;6 and 9;11 (years;months) and evaluates whether children show a speed-accuracy trade-off in their habitual speech production.

Method: Speech samples of varying lengths were collected from 538 typically developing children. Intelligibility was measured as the number of words correctly transcribed by untrained adult listeners, and speaking rate was calculated in number of syllables per second. Regression models estimated the effects of age, utterance length, and speaking rate on intelligibility.

Results: Intelligibility and speaking rate were positively correlated overall but weakly correlated after adjusting for age. In regression analyses, intelligibility increased with age and decreased with utterance length, and there was a trend for intelligibility to decrease with increased speaking rate, especially in longer utterances. At the individual level, for most children, there was a negative effect of speaking rate on intelligibility.

Conclusions: Our findings provide evidence from a large-scale sample for the hypothesis that children's speech is subject to a speed-accuracy trade-off where increased speaking rate leads to reduced articulatory accuracy and hence reduced intelligibility. Further research is needed on how to apply this trade-off in a clinical setting.

Supplemental Material: https://doi.org/10.23641/asha.27964125.

Download full-text PDF

Source
http://dx.doi.org/10.1044/2024_JSLHR-24-00356DOI Listing

Publication Analysis

Top Keywords

speaking rate
32
rate
9
speaking
8
intelligibility
8
intelligibility speaking
8
typically developing
8
developing children
8
speed-accuracy trade-off
8
utterance length
8
increased speaking
8

Similar Publications

Introduction: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX.

Methods: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching.

View Article and Find Full Text PDF

Introduction: Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β-agonist; however, characterization of elderly users of triple therapy is limited. This real-world cohort study describes demographics and clinical characteristics of elderly patients with asthma with and without comorbid chronic obstructive pulmonary disease (COPD) who are new users of triple therapy, and asthma treatment patterns preceding triple therapy initiation.

Methods: This retrospective cohort study used administrative claims data from the Optum Clinformatics Data Mart database.

View Article and Find Full Text PDF

Significance of adding chemotherapy to radiotherapy in the treatment of T2N0 glottic cancer.

Jpn J Clin Oncol

January 2025

Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.

The prognosis for T2N0 glottic squamous cell carcinoma (SCC) is generally favorable, with a 5-year overall survival rate of 79%-96% achieved with radiotherapy (RT), the standard nonsurgical treatment for this condition. However, the local control rate for T2N0 glottic SCC treated with RT remains suboptimal, with a 5-year local control rate of only 65%-80%. Local residual disease or recurrence following RT for T2N0 glottic SCC often leads to difficulties in laryngeal preservation.

View Article and Find Full Text PDF

Background: People with subclinical atrial fibrillation are at increased risk of stroke, albeit to a lesser extent than those with clinical atrial fibrillation, leading to an ongoing debate regarding the benefit of anticoagulation in these individuals. In the ARTESiA trial, the direct-acting oral anticoagulant apixaban reduced stroke or systemic embolism compared with aspirin in people with subclinical atrial fibrillation, but the risk of major bleeding was increased with apixaban. In a prespecified subgroup analysis of ARTESiA, we tested the hypothesis that people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack, who are known to have an increased risk of recurrent stroke, would show a greater benefit from oral anticoagulation for secondary stroke prevention compared with those without a history of stroke or transient ischaemic attack.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!